Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017

MRI contrast agent can now be used to detect disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in youngest patients, including term neonates

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years

September 6, 2017 — Guerbet LLC USA announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine) for intravenous use with magnetic resonance imaging (MRI) in pediatric patients under two years old, including term neonates. The contrast agent can be used to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

Dotarem was previously approved for this use in patient populations over the age of two.

This supplemental indication fulfills a post marketing requirement, acknowledged when Dotarem was first registered in March 2013, to strictly comply with the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c).

The FDA's review was based on a study showing that at the standard dose (0.1 mmol/kg),1 the pharmacokinetic (PK) and safety profiles in pediatric patients under two were similar to those of older children and adults.

The clinical study enrolled 51 pediatric patients in nine centers, with ages spanning from term neonates to 23 months and with normal renal function. It evaluated 45 pediatric patients for PK profile and safety, including five subjects aged less than one month and nine subjects aged one to three months. It assessed efficacy in a subset of 28 subjects who underwent an MRI examination of brain, spine and associated tissues.

In this pediatric population the observed safety profile of Dotarem was consistent with what has been reported in older populations. In one patient, rash was reported as a moderate adverse event (AE). Serious AEs unrelated to Dotarem were reported in one out of 45 patients. Evaluation of images from contrast-enhanced MRI of the CNS supported extrapolation of CNS efficacy findings reported in adults and older children.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast medium (a kind that provides high molecular stability) available in the United States.

For more information: www.guerbet.com

Read the related article "Recent Trends and Developments in Contrast Media."
 

 

References

1. Dotarem (gadoterate meglumine) US Prescribing Information


Related Content

News | Radiology Business

February 2, 2023 — Five additional imaging centers across Allegheny Health Network (AHN) have been recognized by the ...

Time February 02, 2023
arrow
News | Radiation Oncology

February 2, 2023 — The V Foundation, a top cancer research charity, has announced the establishment of a new grant ...

Time February 02, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

February 1, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), MRI ...

Time February 01, 2023
arrow
News | MRI Breast

February 1, 2023 — Compared to other common supplemental screening methods, breast MRI was superior at detecting breast ...

Time February 01, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

January 25, 2023 — On November 11th, 2022 at the Southern Hills Hospital in Las Vegas, USA, Robotic Spine Surgeon Dr ...

Time January 25, 2023
arrow
News | Breast Imaging

January 24, 2023 — For patients with cancer, lengthy delays in treatment can decrease their chances of survival. In an ...

Time January 24, 2023
arrow
News | Artificial Intelligence

January 20, 2023 — Artificial intelligence (AI) can reconstruct coarsely-sampled, rapid magnetic resonance imaging (MRI) ...

Time January 20, 2023
arrow
News | Digital Pathology

January 19, 2023 — In an effort to speed up the research study process, Deciphex has announced the rollout of its ...

Time January 19, 2023
arrow
Feature | Contrast Media Injectors | By Christine Book

The vital, and growing role of contrast media, and the medical devices employed to inject the agent into the body ...

Time January 19, 2023
arrow
News | Radiology Business

January 18, 2023 — Addressing the growing demand for medical imaging and a shortage of radiologists, Bayer announced the ...

Time January 18, 2023
arrow
Subscribe Now